Eli Lilly GLP-1 Selloff and Citi Bull Case
Analysis based on 6 articles · First reported Sep 14, 2026 · Last updated Sep 22, 2026
The event is a single-stock repricing story in the obesity and diabetes franchise: Lilly's pullback on pricing and IPR&D charges has widened the gap to analyst targets, drawing fresh buy-side attention to the GLP-1 category. A sustained price war in incretins would pressure margins across Lilly, Novo Nordisk and clinical-stage peers, while pipeline catalysts such as retatrutide and oral GLP-1 expansion could re-rate the whole sector higher.
Eli Lilly and Company shares fell roughly 7-8% over the month preceding mid-September 2026, sliding from about $1,255 to around $1,115-1,165, even as the broader S&P 500 advanced. The decline followed realized U.S. price declines of about 9% excluding rebate adjustments, international pricing compression after Mounjaro's inclusion in China's National Reimbursement Drug List, $2.78 billion in acquired IPR&D charges from deals including Orna, Kelonia, Ajax and Centessa, and competitive noise from Novo Nordisk's post-Wegovy strategy update. Operationally the company still beat: Q2 revenue beat consensus by 11.06% and EPS by 27.27%, with Mounjaro and Zepbound generating a combined $14.9 billion in quarterly revenue, and full-year 2026 revenue guidance was raised to $85-87 billion. Citigroup analyst Geoff Meacham reiterated a Buy rating and a Street-high $1,600 price target, implying roughly 37-45% upside, arguing the selling is overdone and that Lilly holds about 60% global share of the obesity and type 2 diabetes markets. The consensus target sits near $1,318-1,325, implying about 14-18% upside. Catalysts cited include a retatrutide BLA submission targeted for Q1 2027, the oral GLP-1 Foundayo ramp, and the United States — Medicare GLP-1 Bridge Program granting 20 million eligible Americans coverage at $50 per month. Peer comparisons show Novo Nordisk with roughly 10-17% implied upside, Merck about 6%, Pfizer about 4%, and Viking Therapeutics about 207% on binary clinical-stage risk.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard